trial

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

NCTId NCT06179108
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 359 (actual)
Sponsored by LB Pharmaceuticals Inc.
Primary completion 2024-12-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
359 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2023-11-29
Primary completion
2024-12-04
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
LB-102

Sponsors

LB Pharmaceuticals Inc.Lead Sponsor

Investigators

1
John M Kane, MDPrincipal Investigator

Sites

25 total
Bentonville, United StatesLittle Rock, United StatesRogers, United StatesBellflower, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesRiverside, United StatesSanta Ana, United StatesHollywood, United StatesHollywood, United States

Linked catalysts

1
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB — primary completion2024-12-04

Facts & assertions

4 sourced
Enrollment
359
Phase
PHASE2
Primary Completion Date
2024-12-04
Status
COMPLETED
relationships
The graph out of here
drug
LB-102
drug
lead_sponsor
LB Pharmaceuticals Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
John M Kane, MD
person